Hepatic Disease in HIV-Infected Patients
Summary
- HIV infection can accelerate progression of HBV-related liver disease
- US guidelines recommend initiating ART that includes 2 agents active against HBV in all HBV/HIV-coinfected patients regardless of CD4+ cell count or HBV disease status (Management Guidelines)[DHHS ART]
- Emtricitabine/tenofovir DF, emtricitabine/tenofovir AF, or tenofovir DF or tenofovir AF plus lamivudine is recommended as the NRTI backbone of a 3-drug antiretroviral regimen, which will result in effective treatment of both infections
Patients Refusing or Unable to Tolerate HIV Therapy or Who Are HIV Long-term Nonprogressors
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content